ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "autoimmune diseases"

  • Abstract Number: 826 • 2019 ACR/ARP Annual Meeting

    Immune-Mediated Inflammatory Diseases (IMID) Collectively Rank Among the Leading Causes of Death

    Meifang Wu1, Eric Yen 2 and Ram Raj Singh 2, 1UCLA David Geffen School of Medicine, Los Angeles, CA, 2UCLA, Los Angeles

    Background/Purpose: Almost every organ system can be affected by primary immune-mediated diseases characterized by inflammation and therapeutic response to immune-suppressive or anti-inflammatory drugs. These diseases…
  • Abstract Number: 2114 • 2019 ACR/ARP Annual Meeting

    Risk Factors for Cytomegalovirus Infection in Patients with Autoimmune Diseases

    Daisuke Kobayashi1, Sayuri Takamura 2, Yoko Wada 3, Takeshi Kuroda 4 and Ichiei Narita 1, 1Division of Clinical Nephrology and Rheumatology, Niigata University, Niigata, Niigata, Japan, 2Division of Clinical Nephrology and Rheumatology, Niigata University, Niigata, Japan, 3Niigata Rinko Hospital, Niigata, Niigata, Japan, 4Health administration office, Niigata University, Niigata, Niigata, Japan

    Background/Purpose: Intensive immunosuppressive treatment is often required for patients with autoimmune diseases, and those who are thus treated have a high risk of opportunistic infections.…
  • Abstract Number: 880 • 2019 ACR/ARP Annual Meeting

    Diseased Lupus Nephritis Kidneys Serve as a Primary Site of Systemic Autoimmune Development

    Matthew Woodruff1, Christopher Tipton 1, Jennifer Hom 1 and Iñaki Sanz 1, 1Emory University, Atlanta, GA

    Background/Purpose: Lupus nephritis (LN) is an autoimmune destruction of the kidney glomeruli and loss of kidney function affecting almost half of lupus patients. Although the…
  • Abstract Number: 2150 • 2019 ACR/ARP Annual Meeting

    Frequency of Polyautoimmunity in a Tertiary Hospital

    Elena Grau García1, José Ivorra Cortés 1, Jorge Juan Fragio Gil 1, Roxana Gonzalez Mazarío 1, Marta de la Rubia Navarro 1, Cristóbal Pavez Perales 1, Cristina Alcañiz Escandell 1, Inmaculada Chalmeta Verdejo 1, Luis González Puig 1, Isabel Martínez Cordellat 1, Rosa Negueroles Albuixech 1, José Eloy Oller Rodríguez 2, Francisco Miguel Ortiz-Sanjuán 1, Elvira Vicens Bernabeu 1, Carmen Nájera Herranz 1, Inés Cánovas Olmos 1, Samuel Leal Rodriguez 1 and José Andrés Román Ivorra 1, 1Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, 2Rheumatology Department. HUP La Fe, v, Comunidad Valenciana, Spain

    Background/Purpose: Polyautoimmunity (PAI) is the presence of more than one Autoimmune Disease (AID) in one patient. PAI have been reported in different AIDs as systemic…
  • Abstract Number: 1076 • 2019 ACR/ARP Annual Meeting

    Incidence of Non-serious Infections Among Live Born Infants Born to Mothers Who Used Biologic Medications During Pregnancy for the Treatment of Autoimmune Diseases

    Christina Chambers1, Yunjun Luo 2, Diana L. Johnson 2, Kenneth Lyons Jones 2 and Ronghui Xu 2, 1University of California San Diego, La Jolla, 2University of California, San Diego, La Jolla

    Background/Purpose: In infants whose mothers were treated with biologic therapies during pregnancy, there has been a theoretical concern regarding potential risk of infections.  Several recent…
  • Abstract Number: 2155 • 2019 ACR/ARP Annual Meeting

    The Spectrum of Interstitial Lung Disease Associated with Autoimmune Diseases: Data of a 3-Year-Prospective Study from a Referral Center of Lung Transplantation

    Sara Remuzgo-Martínez1, Diana Prieto-Peña 2, Mónica Calderón-Goercke 2, Victor Manuel Mora Cuesta 3, David Iturbe Fernández 1, Sonia M. Fernández Rozas 3, Jose Manuel Cifrian Martínez 3 and Miguel Angel González-Gay 4, 1Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, Santander, Spain, 2Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL; and Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain, Santander, Spain, 3Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL; and Pneumology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain, Santander, Spain, 4Universidad de Cantabria and IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain

    Background/Purpose: Interstitial lung disease (ILD) occurs in approximately 15% of patients with autoimmune diseases (AD) [1]. Its presence is associated with an increased risk of…
  • Abstract Number: 1077 • 2019 ACR/ARP Annual Meeting

    Mediation of Adverse Pregnancy Outcomes in Autoimmune Conditions by Pregnancy Complications

    Christina Chambers1, Gretchen Bandoli 2, Namrata Singh 3, Jennifer Strouse 4, Rebecca Baer 5, Brittney Donovan 6, Sky Feuer 7, Nichole Nidey 6, Kelli Ryckman 6 and Laura Jelliffe-Pawlowski 7, 1University of California San Diego, La Jolla, 2University of California, San Diego, La Jolla, 3University of Iowa, Iowa City, 4University of Iowa Hospitals and Clinics, Iowa City, 5UCSD, La Jolla, 6UIOWA, Iowa City, 7UCSF, San Francisco

    Background/Purpose: Autoimmune conditions are associated with an increased risk of adverse pregnancy complications and outcomes, suggesting that pregnancy complications may mediate the excess risk. We…
  • Abstract Number: 2296 • 2019 ACR/ARP Annual Meeting

    Assisted Reproductive Technology in Patients with Inflammatory and Autoimmune Rheumatic Disease

    Elisa Trujillo1 and Erika Padrón 1, 1Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain

    Background/Purpose: Women with chronic inflammatory and autoimmune diseases increasingly solicit assisted reproductive techniques (ART) due to infertility, but there is little information about success rates…
  • Abstract Number: 1270 • 2019 ACR/ARP Annual Meeting

    Effectiveness and Safety of Off-label Use of Tocilizumab in Refractory Autoimmune Diseases: A Multicenter Study

    Martin Michaud1, Thomas Sene 2, Pascal Chazerain 2, Geoffrey Urbanski 3, Frederique Retornaz 4, Boris Bienvenu 5, Laurent Chiche 4, Florian Catros 6, Laurent Sailler 7, Laurent Alric 8, Jean Thomas Giraud 9, Léo Caudrelier 10, Slim Lassoued 10, Sophie Ancellin 6, Olivier Lidove 2 and Francis Gaches 6, 1Joseph Ducuing Hospital, Toulouse, France, 2Hôpital Croix Saint Simon, Paris, France, 3CHU Angers, Angers, France, 4Hôpital Européen, Marseille, France, 5Hôpital Saint Joseph, Marseille, France, 6Hôpital Joseph Ducuing, Toulouse, France, 7University Hospital of Toulouse, Toulouse, France, 8CHU Toulouse, Toulouse, France, 9Hôpital de Tarbes, Tarbes, France, 10Hôpital de Cahors, Cahors, France

    Background/Purpose: There is increasing evidence of Tocilizumab (TCZ) efficacy in refractory auto-immune diseases. The present study aimed at evaluating the real-world experience of using TCZ…
  • Abstract Number: 2736 • 2019 ACR/ARP Annual Meeting

    Mucosal-associated Invariant T Cells Can Be Therapeutically Targeted in Lupus

    Goh Murayama1, Asako Chiba 2, Tomohiro Mizuno 3, Atsushi Nomura 2, Taiga Kuga 4, HIrofumi Amano 4, Ken Yamaji 4, Naoto Tamura 4 and Sachiko Miyake 2, 1Department of Internal Medicine and Rhumatology, Juntendo University School of Medicine, Tokyo, Japan, 2Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan, 3Department of Immunlogy, Juntendo University School of Medicine, Tokyo, Japan, 4Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan

    Background/Purpose: Mucosal-associated invariant T (MAIT) cells are innate T cells that are restricted by the nonpolymorphic MHC-related molecule-1 (MR1) and express a semi-invariant TCRα chain:…
  • Abstract Number: 1295 • 2019 ACR/ARP Annual Meeting

    Otoferlin Is Increased in Muscle and PBMCs from Untreated Children with Juvenile Dermatomyositis: Possible Association with Decreased Circulating Natural Killer Cells

    Lauren Pachman1, Wil Marin 2, Gabrielle Morgan 1, Megan L. Curran 3, Kaveh Ardalan 4, Chiang-Ching Huang 5 and Eli Roberson 6, 1Northwestern University, Chicago, 2Ann and Robert H. Lurie Childrens Hospital of Chicago, Chicago, IL, 3University of Colorado, Aurora, CO, 4Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 5University of Milwaukee, Milwaukee, WI, 6Washington University at St.Louis, St.Louis, MO

    Background/Purpose: Juvenile Dermatomyositis (JDM) is a rare inflammatory myopathy in which the immunoregulatory control is not well understood.  Collaboration with A.R.  French, MD/PhD, documented   the…
  • Abstract Number: 2741 • 2019 ACR/ARP Annual Meeting

    Integration of Single Cells from Inflammatory Disease Tissues Reveals Common and Unique Pathogenic Cell States

    Fan Zhang1, Joseph Mears 1, ilya Korsunsky 1, Kevin Wei 2, Anna Helena Jonsson 2, Deepak Rao 1, Edy Kim 3, Laura Donlin 4, Jill Buyon 5, Michelle Petri 6, Chaim Putterman 7, Thomas Tuschl 8, Nir Hacohen 9, Betty Diamond 10, Michael Brenner 11 and Soumya Raychaudhuri 1, 1Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 3Brigham and Women's Hospital, Boton, MA, 4Hospital For Special Surgery, New York, NY, 5New York University School of Medicine, New York, NY, 6Johns Hopkins University School of Medicine, Baltimore, MD, 7Albert Einstein College of Medicine, New York, NY, 8Rockefeller Research Laboratories, New York, 9Broad Institute, Cambridge, 10Feinstein Institutes for Medical Research, Manhasset, 11Brigham and Women’s Hospital:, Boston

    Background/Purpose: Different autoimmune diseases can co-exist in an individual and share similar genetic associations, autoimmune signaling pathways, and clinical manifestations. However, autoimmune diseases present varied…
  • Abstract Number: 1339 • 2019 ACR/ARP Annual Meeting

    Risk of Immunotherapy Related Toxicity in Patients with Rheumatoid Arthritis

    Elizaveta Efuni 1, Samuel Cytryn 2, Patrick Boland 2 and Sabina Sandigursky3, 1New York University School of Medicine, New York, NY, 2NYU Langone Health, New York, 3NYU Langone Health, New York, NY

    Background/Purpose: Immune checkpoint inhibitors (ICIs) have changed the therapeutic landscape in oncology leading to cures in some cancer types. However, patients with pre-existing autoimmune diseases…
  • Abstract Number: 2780 • 2019 ACR/ARP Annual Meeting

    Identification of SLE Subgroups at Risk for Poor Outcomes After Hydroxychloroquine Taper or Discontinuation

    Celline C. Almeida-Brasil 1, Evelyne Vinet 2, Christian Pineau 2 and Sasha Bernatsky1, 1Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 2McGill University Health Centre, Montreal, QC, Canada

    Background/Purpose: The risks and benefits of long-term hydroxychloroquine (HCQ) use in systemic lupus erythematosus (SLE), versus tapering or stopping, remain uncertain. We aimed to identify predictors of…
  • Abstract Number: 1628 • 2019 ACR/ARP Annual Meeting

    Lung Function Decline in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease in the SENSCIS Trial: Subgroup Analysis by Time Since First Non-Raynaud Symptom

    Aryeh Fischer1, Oliver Distler 2, Dinesh Khanna 3, Yannick Allanore 4, Anna Maria Hoffmann-Vold 5, Gabriele Valentini 6, Toby Maher 7, Martin Aringer 8, Leslie Meng 9, Margarida Alves 10, Martina Gahlemann 11, Manuel Quaresma 10 and Masataka Kuwana 12, 1University of Colorado School of Medicine, Denver, Colorado, USA, Denver, CO, 2Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, 3Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, 4Dept. of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France, 5Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, 6Dipartimento di Medicina di Precisione, II Policlinico U.O. Reumatologia, Napoli, Italy, Napoli, Italy, 7National Heart and Lung Institute, Imperial College London, UK and National Institute for Health Research Clinical Research Facility, Royal Brompton Hospital, London, UK, London, United Kingdom, 8Division of Rheumatology, Department of Medicine III, University Medical Center & Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany, Dresden, Germany, 9Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Ridgefield, 10Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, 11Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland, 12Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan

    Background/Purpose: Interstitial lung disease (ILD) is a common and usually early manifestation of systemic sclerosis (SSc). Decline in lung function in patients with SSc-ILD is…
  • « Previous Page
  • 1
  • …
  • 89
  • 90
  • 91
  • 92
  • 93
  • …
  • 101
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology